{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:36:16Z","timestamp":1787027776922,"version":"build-2736575974"},"reference-count":238,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008076","name":"Ohio University","doi-asserted-by":"publisher","award":["RP2404"],"award-info":[{"award-number":["RP2404"]}],"id":[{"id":"10.13039\/100008076","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Diabetes Institute Research Incentive Program","award":["DIPF2501"],"award-info":[{"award-number":["DIPF2501"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Ovarian cancer is a devastating disease that is often diagnosed in the late stages. The typical therapeutic approach includes surgery plus cytotoxic drugs such as carboplatin and paclitaxel. In recent years, the advent of poly ADP-ribose polymerase (PARP) inhibitors such as olaparib has offered additional treatment opportunities for patients with BRCA mutations or homologous recombination deficiencies. Nevertheless, resistance to therapy usually occurs, leading to poor overall survival. Therefore, novel treatments are needed for this disease. One of the obstacles to successful treatment is the highly immunosuppressive nature of the ovarian cancer microenvironment. Recent strategies for the treatment of ovarian cancer and other types of cancer involve targeting the metabolism of cancer cells and other cells of the tumor microenvironment. One drug that has been investigated both in preclinical studies and clinical trials as an antitumor agent is metformin. This drug, typically used for the treatment of type-2 diabetes for its capability to lower blood glucose, can directly affect cancer cell growth and survival by activating the AMPK (adenosine monophosphate-activated protein kinase) pathway. Furthermore, it can affect the phenotype of other cells of the tumor microenvironment such as macrophages and T cells. In this review, we summarize the main characteristics of ovarian cancer and describe preclinical studies and clinical trials involving metformin as a therapeutic agent for this disease.<\/jats:p>","DOI":"10.3390\/biom16030413","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T10:43:27Z","timestamp":1773225807000},"page":"413","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Metformin\u2014A Type 2 Diabetes Mellitus Drug\u2014And Ovarian Cancer: Anticancer Mechanisms and Therapeutic Implications"],"prefix":"10.3390","volume":"16","author":[{"given":"Emma","family":"Sielski","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, College of Osteopathic Medicine, Academic Research Center, Ohio University, Athens, OH 45701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al-Noumani","family":"Shuhd","sequence":"additional","affiliation":[{"name":"Biomedical Engineering Program, Department of Chemical and Biomolecular Engineering, Russ College of Engineering and Technology, Ohio University, Athens, OH 45701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Bower","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, College of Osteopathic Medicine, Academic Research Center, Ohio University, Athens, OH 45701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Cunningham","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, College of Osteopathic Medicine, Academic Research Center, Ohio University, Athens, OH 45701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Beidel","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, College of Osteopathic Medicine, Academic Research Center, Ohio University, Athens, OH 45701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa","family":"Luchianova","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, College of Osteopathic Medicine, Academic Research Center, Ohio University, Athens, OH 45701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cecilia","family":"Courreges","sequence":"additional","affiliation":[{"name":"Clinical and Translational Research Unit, Research and Grants, HCOM, Ohio University, Athens, OH 45701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3049-6150","authenticated-orcid":false,"given":"Fabian","family":"Benencia","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, College of Osteopathic Medicine, Academic Research Center, Ohio University, Athens, OH 45701, USA"},{"name":"Biomedical Engineering Program, Department of Chemical and Biomolecular Engineering, Russ College of Engineering and Technology, Ohio University, Athens, OH 45701, USA"},{"name":"Molecular and Cell Biology Program, Ohio University, Athens, OH 45701, USA"},{"name":"Diabetes Institute, Ohio University, Athens, OH 45701, USA"},{"name":"Institute for Molecular Medicine and Aging, Ohio University, Athens, OH 45701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.21037\/cco-20-31","article-title":"Ovarian carcinoma: Pathology review with an emphasis in their molecular characteristics","volume":"9","year":"2020","journal-title":"Chin. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1136\/ijgc-2024-005305","article-title":"Molecular changes driving low-grade serous ovarian cancer and implications for treatment","volume":"34","author":"Kelliher","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Azzalini, E., Stanta, G., Canzonieri, V., and Bonin, S. (2023). Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242015077"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"9511","DOI":"10.1007\/s11033-023-08760-3","article-title":"High-grade serous ovarian carcinoma, the \u201cAchiles\u2019 hill\u201d for clinicians and molecular biologists: A molecular insight","volume":"50","author":"Bhattacharya","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nature11979","article-title":"Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche","volume":"495","author":"Hwang","year":"2013","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1177\/1066896919838347","article-title":"Ovarian Carcinosarcoma and Concurrent Serous Tubal Intraepithelial Carcinoma with Next-Generation Sequencing Suggesting an Origin from the Fallopian Tube","volume":"27","author":"See","year":"2019","journal-title":"Int. J. Surg. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Otsuka, I. (2021). Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094409"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.ccell.2024.08.016","article-title":"Ovarian cancer metastasis: Looking beyond the surface","volume":"42","author":"Bayraktar","year":"2024","journal-title":"Cancer Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"114238","DOI":"10.1016\/j.isci.2025.114238","article-title":"High-grade serous ovarian cancer induced in different sites of origin in mice exemplifies diverse features of the human disease","volume":"29","author":"Szabova","year":"2026","journal-title":"iScience"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/path.4353","article-title":"A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development","volume":"233","author":"Kuhn","year":"2014","journal-title":"J. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Tirodkar, T.S., Budiu, R.A., Elishaev, E., Zhang, L., Mony, J.T., Brozick, J., Edwards, R.P., and Vlad, A.M. (2014). MUC1 positive, Kras and Pten driven mouse gynecologic tumors replicate human tumors and vary in survival and nuclear grade based on anatomical location. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0102409"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/1878-0261.12845","article-title":"Constitutive activation of integrin alphavbeta3 contributes to anoikis resistance of ovarian cancer cells","volume":"15","author":"Dolinschek","year":"2021","journal-title":"Mol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Zheng, Z., Li, X., Chen, G., Chen, J., Zhu, X., and Teng, Y. (2023). Transcriptome analyses reveal new insights on key determinants of perineural invasion in high-grade serous ovarian cancer. Front. Cell Dev. Biol., 11.","DOI":"10.3389\/fcell.2023.1109710"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1081\/CNV-200032863","article-title":"NICE guidelines for ovarian cancer: Recommendations versus standard care","volume":"22","author":"Ozols","year":"2004","journal-title":"Cancer Investig."},{"key":"ref_15","first-page":"280","article-title":"Epithelial ovarian cancer: Evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ygyno.2009.08.025","article-title":"Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes","volume":"115","author":"Bristow","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"104603","DOI":"10.1016\/j.critrevonc.2024.104603","article-title":"The multiple facets of ovarian high grade serous carcinoma: A review on morphological, immunohistochemical and molecular features","volume":"208","author":"Santoro","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.1073\/pnas.1601311113","article-title":"Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues","volume":"113","author":"Krimmel","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/1758834017714993","article-title":"BRCA mutation in ovarian cancer: Testing, implications and treatment considerations","volume":"9","author":"Neff","year":"2017","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Boyarskikh, U.A., Gulyaeva, L.F., Avdalyan, A.M., Kechin, A.A., Khrapov, E.A., Lazareva, D.G., Kushlinskii, N.E., Melkonyan, A., Arakelyan, A., and Filipenko, M.L. (2020). Spectrum of TP53 Mutations in BRCA1\/2 Associated High-Grade Serous Ovarian Cancer. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.01103"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1136\/ijgc-2020-001556","article-title":"Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes","volume":"30","author":"Pietragalla","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13048-020-00654-3","article-title":"BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: Mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases","volume":"13","author":"Suszynska","year":"2020","journal-title":"J. Ovarian Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/1471-0528.16411","article-title":"PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: A meta-analysis","volume":"128","author":"Lin","year":"2021","journal-title":"BJOG"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41419-025-07647-4","article-title":"USP28 promotes PARP inhibitor resistance by enhancing SOX9-mediated DNA damage repair in ovarian cancer","volume":"16","author":"Han","year":"2025","journal-title":"Cell Death Dis."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Gomez, M.K., Illuzzi, G., Colomer, C., Churchman, M., Hollis, R.L., O\u2019Connor, M.J., Gourley, C., Leo, E., and Melton, D.W. (2020). Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells. Cancers, 12.","DOI":"10.3390\/cancers12061503"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/mc.23064","article-title":"Activation of Wnt signaling promotes olaparib resistant ovarian cancer","volume":"58","author":"Yamamoto","year":"2019","journal-title":"Mol. Carcinog."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ygyno.2020.01.038","article-title":"CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes","volume":"157","author":"Petersen","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"115320","DOI":"10.1016\/j.ejca.2025.115320","article-title":"Differences in immunogenicity of TP53-mutated cancers with low tumor mutational burden (TMB) A study on TP53mut endometrial-, ovarian- and triple-negative breast cancer","volume":"219","author":"Steger","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-024-00932-9","article-title":"Tumour mutational burden: Clinical utility, challenges and emerging improvements","volume":"21","author":"Budczies","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Morand, S., Devanaboyina, M., Staats, H., Stanbery, L., and Nemunaitis, J. (2021). Ovarian Cancer Immunotherapy and Personalized Medicine. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126532"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"384","DOI":"10.37349\/etat.2024.00224","article-title":"Alteration of glucose metabolism and expression of glucose transporters in ovarian cancer","volume":"5","author":"Qmichou","year":"2024","journal-title":"Explor. Target. Antitumor Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"112876","DOI":"10.1016\/j.intimp.2024.112876","article-title":"Myc-mediated inhibition of HIF1a degradation promotes M2 macrophage polarization and impairs CD8 T cell function through lactic acid secretion in ovarian cancer","volume":"141","author":"Liu","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Tondo-Steele, K., and McLean, K. (2022). The \u201cSweet Spot\u201d of Targeting Tumor Metabolism in Ovarian Cancers. Cancers, 14.","DOI":"10.3390\/cancers14194696"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1159\/000079489","article-title":"GLUT1 mRNA and protein expression in ovarian borderline tumors and cancer","volume":"66","author":"Rudlowski","year":"2004","journal-title":"Oncology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3109\/07357907.2013.849722","article-title":"Overexpression of glucose transporter-1 (GLUT-1) predicts poor prognosis in epithelial ovarian cancer","volume":"31","author":"Cho","year":"2013","journal-title":"Cancer Investig."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Compton, S.L.E., Grieco, J.P., Gollamudi, B., Bae, E., Van Mullekom, J.H., and Schmelz, E.M. (2022). Metabolic Reprogramming of Ovarian Cancer Spheroids during Adhesion. Cancers, 14.","DOI":"10.3390\/cancers14061399"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41416-020-0865-z","article-title":"Ascites-derived ALDH+CD44+ tumour cell subsets endow stemness, metastasis and metabolic switch via PDK4-mediated STAT3\/AKT\/NF-kappaB\/IL-8 signalling in ovarian cancer","volume":"123","author":"Jiang","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Xintaropoulou, C., Ward, C., Wise, A., Queckborner, S., Turnbull, A., Michie, C.O., Williams, A.R.W., Rye, T., Gourley, C., and Langdon, S.P. (2018). Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4521-4"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s12672-025-02364-y","article-title":"Lactic acid metabolism: Gynecological cancer\u2019s Achilles\u2019 heel","volume":"16","author":"Zhang","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.12659\/MSM.915730","article-title":"Knockdown of Hypoxia-Inducible Factor 1alpha (HIF-1alpha) Promotes Autophagy and Inhibits Phosphatidylinositol 3-Kinase (PI3K)\/AKT\/Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Ovarian Cancer Cells","volume":"25","author":"Huang","year":"2019","journal-title":"Med. Sci. Monit."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.bbrc.2020.09.135","article-title":"Combination of metformin and RG7388 enhances inhibition of growth and induction of apoptosis of ovarian cancer cells through the PI3K\/AKT\/mTOR pathway","volume":"533","author":"Cui","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41574-023-00833-4","article-title":"Metformin: Update on mechanisms of action and repurposing potential","volume":"19","author":"Foretz","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/19490976.2017.1405209","article-title":"Modulation of the gut microbiota by metformin improves metabolic profiles in aged obese mice","volume":"9","author":"Lee","year":"2018","journal-title":"Gut Microbes"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Cheng, M., Ren, L., Jia, X., Wang, J., and Cong, B. (2024). Understanding the action mechanisms of metformin in the gastrointestinal tract. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1347047"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"306","DOI":"10.2337\/db07-0381","article-title":"Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP","volume":"57","author":"Kim","year":"2008","journal-title":"Diabetes"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.intimp.2016.10.002","article-title":"AMPK activation by metformin inhibits local innate immune responses in the isolated rat heart by suppression of TLR 4-related pathway","volume":"40","author":"Vaez","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1074\/jbc.M114.604421","article-title":"Metformin activates AMP-activated protein kinase by promoting formation of the alphabetagamma heterotrimeric complex","volume":"290","author":"Meng","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1038\/emm.2016.81","article-title":"Regulation and function of AMPK in physiology and diseases","volume":"48","author":"Jeon","year":"2016","journal-title":"Exp. Mol. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41591-018-0159-7","article-title":"Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase","volume":"24","author":"Hunter","year":"2018","journal-title":"Nat. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nature13270","article-title":"Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase","volume":"510","author":"Madiraju","year":"2014","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41586-022-04431-8","article-title":"Low-dose metformin targets the lysosomal AMPK pathway through PEN2","volume":"603","author":"Ma","year":"2022","journal-title":"Nature"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/jdi.13925","article-title":"New mechanism of metformin action mediated by lysosomal presenilin enhancer 2","volume":"14","author":"Sugawara","year":"2023","journal-title":"J. Diabetes Investig."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Chang, W., Li, W., and Li, P. (2023). The anti-diabetic effects of metformin are mediated by regulating long non-coding RNA. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1256705"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e40221","DOI":"10.1097\/MD.0000000000040221","article-title":"Metformin: Diverse molecular mechanisms, gastrointestinal effects and overcoming intolerance in type 2 Diabetes Mellitus: A review","volume":"103","author":"Mohamed","year":"2024","journal-title":"Medicine"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1080\/13813455.2020.1869265","article-title":"Metformin ameliorates ROS-p53-collagen axis of fibrosis and dyslipidemia in type 2 diabetes mellitus-induced left ventricular injury","volume":"129","author":"Alzamil","year":"2023","journal-title":"Arch. Physiol. Biochem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"105672","DOI":"10.1016\/j.intimp.2019.05.057","article-title":"Preventive role of metformin on peripheral neuropathy induced by diabetes","volume":"74","author":"Los","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.7150\/ijbs.104778","article-title":"Metformin Alleviates Liver Metabolic Dysfunction in Polycystic Ovary Syndrome by Activating the Ethe1\/Keap1\/PINK1 Pathway","volume":"21","author":"Xie","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2528815","DOI":"10.1080\/09513590.2025.2528815","article-title":"Metformin prevents oxidative stress and apoptosis of ovarian granulosa cells in polycystic ovary syndrome via activation of Nrf2-HO-1 pathway","volume":"41","author":"Li","year":"2025","journal-title":"Gynecol. Endocrinol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/01913123.2024.2440479","article-title":"Metformin ameliorates diabetes-induced hepatic ultrastructural damage and the immune biomarker CD86 and inflammation in rats","volume":"49","author":"Alshahrani","year":"2025","journal-title":"Ultrastruct. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e02242","DOI":"10.7554\/eLife.02242","article-title":"Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis","volume":"3","author":"Wheaton","year":"2014","journal-title":"eLife"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.cmet.2016.03.006","article-title":"Metformin Pharmacokinetics in Mouse Tumors: Implications for Human Therapy","volume":"23","author":"Dowling","year":"2016","journal-title":"Cell Metab."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.cmet.2010.03.014","article-title":"Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner","volume":"11","author":"Kalender","year":"2010","journal-title":"Cell Metab."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"15652","DOI":"10.18632\/oncotarget.3404","article-title":"Metformin-induced energy deficiency leads to the inhibition of lipogenesis in prostate cancer cells","volume":"6","author":"Loubiere","year":"2015","journal-title":"Oncotarget"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41598-018-37247-6","article-title":"Metformin prevents cell tumorigenesis through autophagy-related cell death","volume":"9","author":"Baldelli","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Griss, T., Vincent, E.E., Egnatchik, R., Chen, J., Ma, E.H., Faubert, B., Viollet, B., DeBerardinis, R.J., and Jones, R.G. (2015). Metformin Antagonizes Cancer Cell Proliferation by Suppressing Mitochondrial-Dependent Biosynthesis. PLoS Biol., 13.","DOI":"10.1371\/journal.pbio.1002309"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1158\/0008-5472.CAN-09-2994","article-title":"Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission","volume":"69","author":"Hirsch","year":"2009","journal-title":"Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1158\/1535-7163.MCT-09-1186","article-title":"Metformin in cancer therapy: A new perspective for an old antidiabetic drug?","volume":"9","author":"Tanti","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_68","first-page":"163","article-title":"Antitumoral effects of metformin in ovarian cancer","volume":"10","author":"Garrido","year":"2019","journal-title":"Metformin"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ygyno.2011.02.021","article-title":"Induction of apoptosis by metformin in epithelial ovarian cancer: Involvement of the Bcl-2 family proteins","volume":"121","author":"Yasmeen","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s13402-015-0235-7","article-title":"Metformin and epithelial ovarian cancer therapeutics","volume":"38","author":"Patel","year":"2015","journal-title":"Cell. Oncol."},{"key":"ref_71","first-page":"155","article-title":"Effect of metformin on apoptosis induction in ovarian cancer cells","volume":"13","author":"Rogalska","year":"2014","journal-title":"Prz. Menopauzalny"},{"key":"ref_72","first-page":"1899","article-title":"Metformin inhibits ovarian cancer via decreasing H3K27 trimethylation","volume":"52","author":"Tang","year":"2018","journal-title":"Int. J. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/21691401.2019.1573737","article-title":"Enhanced anti-proliferative and pro-apoptotic effects of metformin encapsulated PLGA-PEG nanoparticles on SKOV3 human ovarian carcinoma cells","volume":"47","author":"Faramarzi","year":"2019","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_74","first-page":"2086","article-title":"Effect of metformin on the proliferation, apoptosis, invasion and autophagy of ovarian cancer cells","volume":"18","author":"Zou","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_75","first-page":"3086","article-title":"Metformin inhibits ovarian cancer growth and migration in vitro and in vivo by enhancing cisplatin cytotoxicity","volume":"10","author":"Zheng","year":"2018","journal-title":"Am. J. Transl. Res."},{"key":"ref_76","first-page":"484","article-title":"Inhibitory effect and mechanism of metformin on human ovarian cancer cells SKOV-3 and A2780","volume":"21","author":"Huo","year":"2017","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/mc.22498","article-title":"Metformin induces degradation of cyclin D1 via AMPK\/GSK3beta axis in ovarian cancer","volume":"56","author":"Gwak","year":"2017","journal-title":"Mol. Carcinog."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"102052","DOI":"10.1016\/j.tranon.2024.102052","article-title":"Metformin induces tumor immunogenic cell death in ovarian cancer by activating AMPK pathway","volume":"47","author":"Chen","year":"2024","journal-title":"Transl. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Li, M., Huang, L., Chen, J., Guan, T., Wen, Y., Zhu, Y., Yang, X., Zhang, C., Ma, X., and Wan, R. (2025). AMPK-activated BAP1 regulates pVHL stability and tumor-suppressive functions. Cell Death Differ., 1\u201318.","DOI":"10.1038\/s41418-025-01590-9"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.yexcr.2018.03.030","article-title":"SIRT3 aggravates metformin-induced energy stress and apoptosis in ovarian cancer cells","volume":"367","author":"Wu","year":"2018","journal-title":"Exp. Cell Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"25154","DOI":"10.1074\/jbc.M116.742247","article-title":"Activation of AMP-activated Protein Kinase by Metformin Induces Protein Acetylation in Prostate and Ovarian Cancer Cells","volume":"291","author":"Galdieri","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"10908","DOI":"10.18632\/oncotarget.3434","article-title":"Metformin prevents aggressive ovarian cancer growth driven by high-energy diet: Similarity with calorie restriction","volume":"6","author":"Mert","year":"2015","journal-title":"Oncotarget"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Zhuang, Y., Chan, D.K., Haugrud, A.B., and Miskimins, W.K. (2014). Mechanisms by which low glucose enhances the cytotoxicity of metformin to cancer cells both in vitro and in vivo. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0108444"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ygyno.2008.04.008","article-title":"In vitro metformin anti-neoplastic activity in epithelial ovarian cancer","volume":"110","author":"Gotlieb","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13046-019-1090-6","article-title":"Low glucose and metformin-induced apoptosis of human ovarian cancer cells is connected to ASK1 via mitochondrial and endoplasmic reticulum stress-associated pathways","volume":"38","author":"Ma","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3892\/ijo.2015.3004","article-title":"Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells","volume":"47","author":"Kim","year":"2015","journal-title":"Int. J. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1111\/cas.15524","article-title":"Metformin inhibits the proliferation and invasion of ovarian cancer cells by suppressing tripartite motif-containing 37-induced tumor necrosis factor receptor-associated factor 2 ubiquitination","volume":"113","author":"Zheng","year":"2022","journal-title":"Cancer Sci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"9636897211027819","DOI":"10.1177\/09636897211027819","article-title":"Metformin Antagonizes Ovarian Cancer Cells Malignancy Through MSLN Mediated IL-6\/STAT3 Signaling","volume":"30","author":"Yang","year":"2021","journal-title":"Cell Transplant."},{"key":"ref_89","first-page":"1833","article-title":"MUL1 E3 ligase regulates the antitumor effects of metformin in chemoresistant ovarian cancer cells via AKT degradation","volume":"54","author":"Lee","year":"2019","journal-title":"Int. J. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Garrido, M.P., Salvatierra, R., Valenzuela-Valderrama, M., Vallejos, C., Bruneau, N., Hernandez, A., Vega, M., Selman, A., Quest, A.F.G., and Romero, C. (2020). Metformin Reduces NGF-Induced Tumour Promoter Effects in Epithelial Ovarian Cancer Cells. Pharmaceuticals, 13.","DOI":"10.3390\/ph13100315"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Wu, Y., Zhang, Z., Ren, M., Chen, Y., Zhang, J., Li, J., Gao, F., Bao, Y., Huang, Y., and Yang, X. (2025). Metformin Induces Apoptosis and Ferroptosis of Ovarian Cancer Cells Under Energy Stress Conditions. Cells, 14.","DOI":"10.3390\/cells14030213"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1582-4934.2009.00954.x","article-title":"Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner","volume":"15","author":"Rattan","year":"2011","journal-title":"J. Cell. Mol. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.yexcr.2014.08.028","article-title":"Ovarian tumor-initiating cells display a flexible metabolism","volume":"328","author":"Anderson","year":"2014","journal-title":"Exp. Cell Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s13287-015-0249-0","article-title":"Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44+CD117+ ovarian cancer stem cells","volume":"6","author":"Zhang","year":"2015","journal-title":"Stem Cell Res. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ygyno.2012.07.115","article-title":"Metformin targets ovarian cancer stem cells in vitro and in vivo","volume":"127","author":"Shank","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_96","first-page":"e133247","article-title":"Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer","volume":"5","author":"Brown","year":"2020","journal-title":"JCI Insight"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Mikhael, S., Kurdi, A., Khoueiry-Zgheib, N., Tahtouh, R., Nasr, R., and Hilal, G. (2024). Evaluating synergistic effects of metformin and simvastatin on ovarian cancer cells. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0298127"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.pharep.2017.11.007","article-title":"Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines","volume":"70","author":"Tessarollo","year":"2018","journal-title":"Pharmacol. Rep."},{"key":"ref_99","first-page":"2404","article-title":"Metformin improves the sensitivity of ovarian cancer cells to chemotherapeutic agents","volume":"18","author":"Yang","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_100","first-page":"7557","article-title":"Metformin in combination with cisplatin inhibits cell viability and induces apoptosis of human ovarian cancer cells by inactivating ERK 1\/2","volume":"14","author":"Dang","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"479.e1","DOI":"10.1016\/j.ajog.2014.10.026","article-title":"Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models","volume":"212","author":"Lengyel","year":"2015","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Gralewska, P., Gajek, A., Marczak, A., and Rogalska, A. (2021). Metformin Affects Olaparib Sensitivity through Induction of Apoptosis in Epithelial Ovarian Cancer Cell Lines. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910557"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Almeida-Nunes, D.L., Silva, J.P.N., Nunes, M., Silva, P.M.A., Silvestre, R., Dinis-Oliveira, R.J., Bousbaa, H., and Ricardo, S. (2024). Metformin Impairs Linsitinib Anti-Tumor Effect on Ovarian Cancer Cell Lines. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252211935"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"59458","DOI":"10.18632\/oncotarget.10694","article-title":"Dichloroacetate and metformin synergistically suppress the growth of ovarian cancer cells","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"ref_105","first-page":"4812","article-title":"Targeting cancer cell metabolism: The combination of metformin and 2-Deoxyglucose regulates apoptosis in ovarian cancer cells via p38 MAPK\/JNK signaling pathway","volume":"8","author":"Zhu","year":"2016","journal-title":"Am. J. Transl. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ygyno.2017.05.019","article-title":"Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer","volume":"146","author":"Mert","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"100113","DOI":"10.18632\/oncotarget.22012","article-title":"Phenformin has anti-tumorigenic effects in human ovarian cancer cells and in an orthotopic mouse model of serous ovarian cancer","volume":"8","author":"Jackson","year":"2017","journal-title":"Oncotarget"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/bjc.1998.69","article-title":"Stimulation of the apoptotic response as a basis for the therapeutic synergism of lonidamine and cisplatin in combination in human tumour xenografts","volume":"77","author":"Pratesi","year":"1998","journal-title":"Br. J. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/ijc.2910520524","article-title":"Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells","volume":"52","author":"Silvestrini","year":"1992","journal-title":"Int. J. Cancer"},{"key":"ref_110","first-page":"777","article-title":"Use of lonidamine to potentiate the effect of cisplatin and carboplatin on platinum resistant human ovarian cancer cells","volume":"11","author":"Angioli","year":"1997","journal-title":"Int. J. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/(SICI)1097-0215(19981029)78:3<377::AID-IJC20>3.0.CO;2-2","article-title":"Lonidamine as a modulator of taxol activity in human ovarian cancer cells: Effects on cell cycle and induction of apoptosis","volume":"78","author":"Orlandi","year":"1998","journal-title":"Int. J. Cancer"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1200\/JCO.1997.15.10.3208","article-title":"Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum","volume":"15","author":"Lorusso","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0959-8049(00)00400-7","article-title":"Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study","volume":"37","author":"Lorusso","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"114155","DOI":"10.1016\/j.yexcr.2024.114155","article-title":"Ascites microenvironment conditions the peritoneal pre-metastatic niche to promote the implantation of ovarian tumor spheroids: Involvement of fibrinogen\/fibrin and alphaV and alpha5beta1 integrins","volume":"441","author":"Landras","year":"2024","journal-title":"Exp. Cell Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/s41591-020-0926-0","article-title":"A single-cell landscape of high-grade serous ovarian cancer","volume":"26","author":"Izar","year":"2020","journal-title":"Nat. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e2200197","DOI":"10.1002\/adbi.202200197","article-title":"Extracellular Matrix Modulates Outgrowth Dynamics in Ovarian Cancer","volume":"6","author":"Alshehri","year":"2022","journal-title":"Adv. Biol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1007\/s13277-015-4538-0","article-title":"Regulatory B cells contribute to the impaired antitumor immunity in ovarian cancer patients","volume":"37","author":"Wei","year":"2016","journal-title":"Tumour Biol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41586-020-03144-0","article-title":"IgA transcytosis and antigen recognition govern ovarian cancer immunity","volume":"591","author":"Biswas","year":"2021","journal-title":"Nature"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"7228","DOI":"10.1038\/s41598-018-25589-0","article-title":"The mechanical microenvironment regulates ovarian cancer cell morphology, migration, and spheroid disaggregation","volume":"8","author":"McKenzie","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Li, Y., Tian, R., Liu, J., Li, J., Tan, H., Wu, Q., and Fu, X. (2022). Deciphering the immune landscape dominated by cancer-associated fibroblasts to investigate their potential in indicating prognosis and guiding therapeutic regimens in high grade serous ovarian carcinoma. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.940801"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Xu, Y., Sun, D., He, J., and Yao, Q. (2025). Cancer-associated fibroblasts in ovarian cancer: Research progress. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1504762"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Asante, D.B., Tierno, D., Woode, M., and Scaggiante, B. (2024). Angiogenesis and Ovarian Cancer: What Potential Do Different Subtypes of Circulating Endothelial Cells Have for Clinical Application?. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25116283"},{"key":"ref_123","first-page":"193","article-title":"A novel mechanism of neovascularization in peritoneal dissemination via cancer-associated mesothelial cells affected by TGF-beta derived from ovarian cancer","volume":"39","author":"Fujikake","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"758","DOI":"10.4161\/cbt.7.5.5765","article-title":"Functional significance of VEGF-a in human ovarian carcinoma: Role in vasculogenic mimicry","volume":"7","author":"Wang","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Zhao, X., Jia, Y., Wen, W., Shao, C., Zou, Q., Chen, L., Jiang, H., Yang, G., Wang, W., and Zhang, C. (2025). Establishment and validation of a prognostic model based on vasculogenic mimicry-related gene clustering in ovarian cancer. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1575694"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Yu, P., Wang, Y., Yuan, D., Sun, Y., Qin, S., and Li, T. (2023). Vascular normalization: Reshaping the tumor microenvironment and augmenting antitumor immunity for ovarian cancer. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1276694"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/bjc.2017.297","article-title":"Crosstalk between TEMs and endothelial cells modulates angiogenesis and metastasis via IGF1-IGF1R signalling in epithelial ovarian cancer","volume":"117","author":"Wang","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin(R)) in cancer treatment: A review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Roberts, J.N.T., Courel, S., Schlumbrecht, M.P., Nair, N., and Sinno, A.K. (2025). Improved progression-free survival with mirvetuximab and bevacizumab in platinum-resistant ovarian cancer: A retrospective real-world analysis. Int. J. Gynecol. Cancer, in press.","DOI":"10.1016\/j.ijgc.2025.102879"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e35821","DOI":"10.1002\/cncr.35821","article-title":"The BEV1L study: Do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?","volume":"131","author":"Duska","year":"2025","journal-title":"Cancer"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nm1699","article-title":"Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy","volume":"14","author":"Buckanovich","year":"2008","journal-title":"Nat. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nm.3541","article-title":"Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors","volume":"20","author":"Motz","year":"2014","journal-title":"Nat. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-020-00858-6","article-title":"Vasculogenic mimicry in carcinogenesis and clinical applications","volume":"13","author":"Luo","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"109116","DOI":"10.1016\/j.intimp.2022.109116","article-title":"Immunotherapy checkpoints in ovarian cancer vasculogenic mimicry: Tumor immune microenvironments, and drugs","volume":"111","author":"Hu","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3892\/or.2014.3229","article-title":"Wnt5a promotes vasculogenic mimicry and epithelial-mesenchymal transition via protein kinase Calpha in epithelial ovarian cancer","volume":"32","author":"Qi","year":"2014","journal-title":"Oncol. Rep."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ygyno.2014.02.034","article-title":"Hypoxia promotes vasculogenic mimicry formation by inducing epithelial-mesenchymal transition in ovarian carcinoma","volume":"133","author":"Du","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1073\/pnas.1525349113","article-title":"Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages","volume":"113","author":"Peterson","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1158\/1078-0432.CCR-18-0220","article-title":"Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer","volume":"25","author":"Matuszewska","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"412","DOI":"10.7150\/jca.11242","article-title":"Prognostic significance of lymphovascular space invasion in epithelial ovarian cancer","volume":"6","author":"Chen","year":"2015","journal-title":"J. Cancer"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s00262-024-03911-2","article-title":"Tertiary lymphoid structures in high-grade serous tubo-ovarian carcinoma: Anatomical site matters","volume":"74","author":"Tran","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1158\/0008-5472.CAN-19-1999","article-title":"Adipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance","volume":"80","author":"Mukherjee","year":"2020","journal-title":"Cancer Res."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Aird, R., Wills, J., Roby, K.F., Benezech, C., Stimson, R.H., Wabitsch, M., Pollard, J.W., Finch, A., and Michailidou, Z. (2022). Hypoxia-driven metabolic reprogramming of adipocytes fuels cancer cell proliferation. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.989523"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1038\/s42255-023-00879-8","article-title":"Adipocytes reprogram cancer cell metabolism by diverting glucose towards glycerol-3-phosphate thereby promoting metastasis","volume":"5","author":"Mukherjee","year":"2023","journal-title":"Nat. Metab."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.62347\/XZRI9189","article-title":"Cancer-associated adipocytes in the ovarian cancer microenvironment","volume":"14","author":"Cai","year":"2024","journal-title":"Am. J. Cancer Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13048-020-00718-4","article-title":"Adipocytes: Active facilitators in epithelial ovarian cancer progression?","volume":"13","author":"Dai","year":"2020","journal-title":"J. Ovarian Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"13316","DOI":"10.1038\/s41598-019-49649-1","article-title":"Adipocytes promote ovarian cancer chemoresistance","volume":"9","author":"Yang","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1186\/s12964-024-01806-4","article-title":"Adipocyte derived exosomes promote cell invasion and challenge paclitaxel efficacy in ovarian cancer","volume":"22","author":"Williams","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Stout, A., Facey, N., Bhatnagar, A., Rice, K., Berditchevski, F., Kearns, D., Metcalf, A., Elghobashy, A., and Shaaban, A.M. (2024). Profiling of Tumour-Infiltrating Lymphocytes and Tumour-Associated Macrophages in Ovarian Epithelial Cancer-Relation to Tumour Characteristics and Impact on Prognosis. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25084524"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1186\/s12967-025-06643-8","article-title":"Unraveling the role of M2 TAMs in ovarian cancer dynamics: A systematic review","volume":"23","author":"Wang","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Xu, C., Chen, J., Tan, M., and Tan, Q. (2025). The role of macrophage polarization in ovarian cancer: From molecular mechanism to therapeutic potentials. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1543096"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/BF02893460","article-title":"Immunophenotyping of tumor-infiltrating mononuclear cells in ovarian carcinoma","volume":"10","author":"Alla","year":"2004","journal-title":"Pathol. Oncol. Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1006\/gyno.1998.5292","article-title":"Macrophages and microvessel density in tumors of the ovary","volume":"73","author":"Orre","year":"1999","journal-title":"Gynecol. Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.canlet.2019.05.029","article-title":"Alternatively activated macrophage-derived secretome stimulates ovarian cancer spheroid spreading through a JAK2\/STAT3 pathway","volume":"458","author":"Fogg","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0304-3835(92)90186-Y","article-title":"Angiogenic effects of macrophages isolated from ascitic fluid aspirated from women with advanced ovarian cancer","volume":"62","author":"Sheid","year":"1992","journal-title":"Cancer Lett."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"e000979","DOI":"10.1136\/jitc-2020-000979","article-title":"M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer","volume":"8","author":"Hensler","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"6096","DOI":"10.1038\/s41598-020-63276-1","article-title":"Role of M1-polarized tumor-associated macrophages in the prognosis of advanced ovarian cancer patients","volume":"10","author":"Maccio","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"23210","DOI":"10.18632\/aging.203613","article-title":"Integrated analysis of tumor-associated macrophage infiltration and prognosis in ovarian cancer","volume":"13","author":"Tan","year":"2021","journal-title":"Aging"},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Zhao, F., Jiang, X., Li, Y., Huang, T., Xiahou, Z., Nie, W., and Li, Q. (2024). Characterizing tumor biology and immune microenvironment in high-grade serous ovarian cancer via single-cell RNA sequencing: Insights for targeted and personalized immunotherapy strategies. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1500153"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Wang, J., Zhu, W., Li, X., Wu, Y., Ma, W., Wang, Y., Zhao, W., Wei, F., and Wang, W. (2025). Transcriptome analysis of ovarian cancer uncovers association between tumor-related inflammation\/immunity and patient outcome. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1500251"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1172\/JCI87252","article-title":"Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer","volume":"126","author":"Yin","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3892\/ijo.2024.5705","article-title":"Beyond tumor-associated macrophages involved in spheroid formation and dissemination: Novel insights for ovarian cancer therapy (Review)","volume":"65","author":"Liu","year":"2024","journal-title":"Int. J. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41467-021-20893-2","article-title":"CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy","volume":"12","author":"Lynn","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1158\/2326-6066.CIR-21-1075","article-title":"Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity","volume":"10","author":"Mollaoglu","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1158\/1535-7163.MCT-17-0688","article-title":"Therapeutic Impact of Nanoparticle Therapy Targeting Tumor-Associated Macrophages","volume":"17","author":"Penn","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Li, Y., Zhao, L., Tian, Y., Zhou, Q., Liu, X., Yang, S., Xu, J., Zou, C., Zhang, J., and Luo, H. (2025). Uncovering key regulatory pathways and prognostic biomarkers in the tumor microenvironment of high-grade serous ovarian cancer through single-cell RNA sequencing and experimental validation. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1591430"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.trsl.2024.05.013","article-title":"DC-derived CXCL10 promotes CTL activation to suppress ovarian cancer","volume":"272","author":"Dong","year":"2024","journal-title":"Transl. Res."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Salvi","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejca.2020.04.036","article-title":"Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer","volume":"135","author":"Sarivalasis","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"7684","DOI":"10.1158\/0008-5472.CAN-08-1167","article-title":"Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity","volume":"68","author":"Huarte","year":"2008","journal-title":"Cancer Res."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.immuni.2012.10.018","article-title":"Human inflammatory dendritic cells induce Th17 cell differentiation","volume":"38","author":"Segura","year":"2013","journal-title":"Immunity"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"e1185583","DOI":"10.1080\/2162402X.2016.1185583","article-title":"Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103+ dendritic cells in late-stage ovarian cancer","volume":"5","author":"Flies","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Mabuchi, S., Sasano, T., and Komura, N. (2021). Targeting Myeloid-Derived Suppressor Cells in Ovarian Cancer. Cells, 10.","DOI":"10.3390\/cells10020329"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Okla, K., Czerwonka, A., Wawruszak, A., Bobinski, M., Bilska, M., Tarkowski, R., Bednarek, W., Wertel, I., and Kotarski, J. (2019). Clinical Relevance and Immunosuppressive Pattern of Circulating and Infiltrating Subsets of Myeloid-Derived Suppressor Cells (MDSCs) in Epithelial Ovarian Cancer. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00691"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1111\/febs.15311","article-title":"Myeloid-derived suppressor cells promote epithelial ovarian cancer cell stemness by inducing the CSF2\/p-STAT3 signalling pathway","volume":"287","author":"Li","year":"2020","journal-title":"FEBS J."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1158\/1078-0432.CCR-16-0387","article-title":"Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells","volume":"23","author":"Horikawa","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Okla, K. (2023). Myeloid-Derived Suppressor Cells (MDSCs) in Ovarian Cancer-Looking Back and Forward. Cells, 12.","DOI":"10.3390\/cells12141912"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1136\/ijgc-2019-000521","article-title":"Myeloid-derived suppressor cells at diagnosis may discriminate between benign and malignant ovarian tumors","volume":"29","author":"Coosemans","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41416-018-0339-8","article-title":"Mitochondrial DNA in the tumour microenvironment activates neutrophils and is associated with worse outcomes in patients with advanced epithelial ovarian cancer","volume":"120","author":"Singel","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/s41416-020-1026-0","article-title":"Tumour-associated neutrophils orchestrate intratumoural IL-8-driven immune evasion through Jagged2 activation in ovarian cancer","volume":"123","author":"Yang","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Masucci, M.T., Minopoli, M., and Carriero, M.V. (2019). Tumor Associated Neutrophils. Their Role in Tumorigenesis, Metastasis, Prognosis and Therapy. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01146"},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Cheng, K.C., Lin, Y.H., Wu, D.S., Shih, I.M., and Wang, T.L. (2025). Macrophages and neutrophils in ovarian cancer microenvironment. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1677441"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"323","DOI":"10.5937\/jomb0-46035","article-title":"The prognostic and clinical value of neutrophil-to-lymphocyte ratio (NLR) in ovarian cancer: A systematic review and meta-analysis","volume":"43","author":"Zhang","year":"2024","journal-title":"J. Med. Biochem."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Tian, Y., Li, X., Zhang, H., Wang, Y., Li, H., and Qin, Q. (2024). Serum NLR combined with CA125 and HE4 improves the diagnostic and prognostic efficiency in patients with ovarian cancer. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1494051"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"23196","DOI":"10.1038\/s41598-025-05010-3","article-title":"Neutrophil infiltration in peritoneal metastasis affects prognosis in patients with ovarian cancer","volume":"15","author":"Miyamoto","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41392-025-02242-7","article-title":"Therapeutic potential of tumor-associated neutrophils: Dual role and phenotypic plasticity","volume":"10","author":"Zhou","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ccell.2024.12.004","article-title":"Neutrophil extracellular traps promote pre-metastatic niche formation in the omentum by expanding innate-like B cells that express IL-10","volume":"43","author":"Lee","year":"2025","journal-title":"Cancer Cell"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"e70302","DOI":"10.1111\/jcmm.70302","article-title":"A Neutrophil Extracellular Traps-Related Signature Predicts Clinical Outcomes and Identifies Immune Landscape in Ovarian Cancer","volume":"28","author":"Zhang","year":"2024","journal-title":"J. Cell. Mol. Med."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/jleuko\/qiae166","article-title":"G-CSF induces neutrophil extracellular traps formation and promotes ovarian cancer peritoneal dissemination","volume":"116","author":"Bun","year":"2024","journal-title":"J. Leukoc. Biol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s13048-023-01207-0","article-title":"MUC16 stimulates neutrophils to an inflammatory and immunosuppressive phenotype in ovarian cancer","volume":"16","author":"Wu","year":"2023","journal-title":"J. Ovarian Res."},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Lin, J., He, X.L., Zhang, W.W., and Mo, C.F. (2025). Metabolic reprogramming of tumor-associated neutrophils in tumor treatment and therapeutic resistance. Front. Cell Dev. Biol., 13.","DOI":"10.3389\/fcell.2025.1584987"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"aaa6566","DOI":"10.1126\/science.aaa6566","article-title":"Innate lymphoid cells. Innate lymphoid cells: A new paradigm in immunology","volume":"348","author":"Eberl","year":"2015","journal-title":"Science"},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Kuo, I.C., Brassard, J., Zandstra, P.W., and McNagny, K.M. (2025). Innate lymphoid cells in the spotlight: From biomarkers to blueprint for innovative immunotherapy. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1655730"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s13046-023-02798-8","article-title":"Electrolyte imbalance causes suppression of NK and T cell effector function in malignant ascites","volume":"42","author":"Hrvat","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"eadr4795","DOI":"10.1126\/sciimmunol.adr4795","article-title":"Uptake of lipids from ascites drives NK cell metabolic dysfunction in ovarian cancer","volume":"10","author":"Slattery","year":"2025","journal-title":"Sci. Immunol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"2349347","DOI":"10.1080\/2162402X.2024.2349347","article-title":"Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors","volume":"13","author":"Chung","year":"2024","journal-title":"Oncoimmunology"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"296","DOI":"10.37349\/etat.2024.00219","article-title":"Emerging roles of type 1 innate lymphoid cells in tumour pathogenesis and cancer immunotherapy","volume":"5","author":"Verner","year":"2024","journal-title":"Explor. Target. Antitumor Ther."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"e13284","DOI":"10.1111\/aji.13284","article-title":"Identification of unique clusters of T, dendritic, and innate lymphoid cells in the peritoneal fluid of ovarian cancer patients","volume":"84","author":"Vazquez","year":"2020","journal-title":"Am. J. Reprod. Immunol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1158\/1078-0432.CCR-15-2762","article-title":"Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer","volume":"22","author":"Kroeger","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2011.09.039","article-title":"Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis","volume":"124","author":"Hwang","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"e173290","DOI":"10.1001\/jamaoncol.2017.3290","article-title":"Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer","volume":"3","author":"Goode","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"e179501","DOI":"10.1172\/JCI179501","article-title":"Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer","volume":"134","author":"Nelson","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"Tassi, E., Bergamini, A., Wignall, J., Sant\u2019Angelo, M., Brunetto, E., Balestrieri, C., Redegalli, M., Potenza, A., Abbati, D., and Manfredi, F. (2023). Epithelial ovarian cancer is infiltrated by activated effector T cells co-expressing CD39, PD-1, TIM-3, CD137 and interacting with cancer cells and myeloid cells. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1212444"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat. Med."},{"key":"ref_207","doi-asserted-by":"crossref","unstructured":"Ning, F., Cole, C.B., and Annunziata, C.M. (2020). Driving Immune Responses in the Ovarian Tumor Microenvironment. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.604084"},{"key":"ref_208","first-page":"72","article-title":"Personalized approaches to active immunotherapy in cancer","volume":"1865","author":"Ophir","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Zhang, H., Li, S., Huang, K., Jiang, L., and Wang, Y. (2022). Metformin Alleviates LPS-Induced Acute Lung Injury by Regulating the SIRT1\/NF-kappaB\/NLRP3 Pathway and Inhibiting Endothelial Cell Pyroptosis. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.801337"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"110661","DOI":"10.1016\/j.exger.2019.110661","article-title":"AMPK as a potential pharmacological target for alleviating LPS-induced acute lung injury partly via NLRC4 inflammasome pathway inhibition","volume":"125","author":"He","year":"2019","journal-title":"Exp. Gerontol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00109-024-02465-1","article-title":"Metformin improves cognitive dysfunction through SIRT1\/NLRP3 pathway-mediated neuroinflammation in db\/db mice","volume":"102","author":"Hu","year":"2024","journal-title":"J. Mol. Med."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"e000611","DOI":"10.1136\/lupus-2021-000611","article-title":"Metformin improves renal injury of MRL\/lpr lupus-prone mice via the AMPK\/STAT3 pathway","volume":"9","author":"Chen","year":"2022","journal-title":"Lupus Sci. Med."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.immuni.2021.05.004","article-title":"Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation","volume":"54","author":"Xian","year":"2021","journal-title":"Immunity"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yjmcc.2020.05.016","article-title":"Metformin protects against ischaemic myocardial injury by alleviating autophagy-ROS-NLRP3-mediated inflammatory response in macrophages","volume":"145","author":"Fei","year":"2020","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.mce.2016.06.008","article-title":"Metformin and resveratrol inhibit Drp1-mediated mitochondrial fission and prevent ER stress-associated NLRP3 inflammasome activation in the adipose tissue of diabetic mice","volume":"434","author":"Li","year":"2016","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s10787-025-01702-4","article-title":"NLRP3 inflammasomes pathway: A key target for Metformin","volume":"33","author":"Hosseini","year":"2025","journal-title":"Inflammopharmacology"},{"key":"ref_217","doi-asserted-by":"crossref","unstructured":"Jin, L., Jin, F., Guo, S., Liu, W., Wei, B., Fan, H., Li, G., Zhang, X., Su, S., and Li, R. (2022). Metformin Inhibits NLR Family Pyrin Domain Containing 3 (NLRP)-Relevant Neuroinflammation via an Adenosine-5\u2032-Monophosphate-Activated Protein Kinase (AMPK)-Dependent Pathway to Alleviate Early Brain Injury After Subarachnoid Hemorrhage in Mice. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.796616"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"e005719","DOI":"10.1136\/jitc-2022-005719","article-title":"Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression","volume":"11","author":"Finisguerra","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1073\/pnas.1417636112","article-title":"Immune-mediated antitumor effect by type 2 diabetes drug, metformin","volume":"112","author":"Eikawa","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"e70705","DOI":"10.1096\/fj.202500906R","article-title":"Metformin Enhances PD-L1 Inhibitor Efficacy in Ovarian Cancer by Modulating the Immune Microenvironment and RBMS3 Expression","volume":"39","author":"Zhang","year":"2025","journal-title":"FASEB J."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"e002772","DOI":"10.1136\/jitc-2021-002772","article-title":"Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3","volume":"9","author":"Chung","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1158\/0008-5472.CAN-17-2460","article-title":"Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer","volume":"78","author":"Li","year":"2018","journal-title":"Cancer Res."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1158\/1535-7163.MCT-17-0927","article-title":"Metformin Suppresses Tumor Progression by Inactivating Stromal Fibroblasts in Ovarian Cancer","volume":"17","author":"Xu","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s44276-023-00022-w","article-title":"Metformin may improve the outcome of patients with colorectal cancer and type 2 diabetes mellitus partly through effects on neutrophil extracellular traps","volume":"1","author":"Saito","year":"2023","journal-title":"BJC Rep."},{"key":"ref_225","doi-asserted-by":"crossref","unstructured":"Frasca, D., Diaz, A., Romero, M., and Blomberg, B.B. (2021). Metformin Enhances B Cell Function and Antibody Responses of Elderly Individuals with Type-2 Diabetes Mellitus. Front. Aging, 2.","DOI":"10.3389\/fragi.2021.715981"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"110965","DOI":"10.18632\/oncotarget.20754","article-title":"Increased efficacy of metformin corresponds to differential metabolic effects in the ovarian tumors from obese versus lean mice","volume":"8","author":"Han","year":"2017","journal-title":"Oncotarget"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.18632\/oncotarget.2012","article-title":"Metformin limits the adipocyte tumor-promoting effect on ovarian cancer","volume":"5","author":"Tebbe","year":"2014","journal-title":"Oncotarget"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1007\/s10637-020-00920-7","article-title":"Phase I study of metformin in combination with carboplatin\/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer","volume":"38","author":"Broekman","year":"2020","journal-title":"Investig. New Drugs"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1158\/2767-9764.CRC-22-0260","article-title":"Phase I Study of mTORC1\/2 Inhibitor Sapanisertib (CB-228\/TAK-228) in Combination with Metformin in Patients with mTOR\/AKT\/PI3K Pathway Alterations and Advanced Solid Malignancies","volume":"4","author":"Subbiah","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.3802\/jgo.2023.34.e15","article-title":"A phase II, open-label, non-randomized, prospective study assessing paclitaxel, carboplatin and metformin in the treatment of advanced stage ovarian carcinoma","volume":"34","author":"Micha","year":"2023","journal-title":"J. Gynecol. Oncol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13048-020-00703-x","article-title":"Neoadjuvant metformin added to conventional chemotherapy synergizes anti-proliferative effects in ovarian cancer","volume":"13","author":"Wen","year":"2020","journal-title":"J. Ovarian Res."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/ijgc-2024-005663","article-title":"Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: Combined analysis of four prospective trials of AGO-OVAR and ENGOT\/GCIG collaborators","volume":"34","author":"Denschlag","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_233","doi-asserted-by":"crossref","unstructured":"Torkildsen, C.F., Austdal, M., Iversen, A.C., Bathen, T.F., Giskeodegard, G.F., Nilsen, E.B., Iversen, G.A., Sande, R.K., Bjorge, L., and Thomsen, L.C.V. (2023). Primary Treatment Effects for High-Grade Serous Ovarian Carcinoma Evaluated by Changes in Serum Metabolites and Lipoproteins. Metabolites, 13.","DOI":"10.3390\/metabo13030417"},{"key":"ref_234","doi-asserted-by":"crossref","unstructured":"Torkildsen, C.F., Austdal, M., Jarmund, A.H., Kleinmanns, K., Lamark, E.K., Nilsen, E.B., Stefansson, I., Sande, R.K., Iversen, A.C., and Thomsen, L.C.V. (2024). New immune phenotypes for treatment response in high-grade serous ovarian carcinoma patients. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1394497"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41580-022-00456-z","article-title":"Defining roles of specific reactive oxygen species (ROS) in cell biology and physiology","volume":"23","author":"Sies","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature15726","article-title":"Oxidative stress inhibits distant metastasis by human melanoma cells","volume":"527","author":"Piskounova","year":"2015","journal-title":"Nature"},{"key":"ref_237","first-page":"308re8","article-title":"Antioxidants can increase melanoma metastasis in mice","volume":"7","author":"Ibrahim","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/clpt.2013.21","article-title":"Systems-based discovery advances drug development","volume":"93","author":"Waldman","year":"2013","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/3\/413\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T11:15:58Z","timestamp":1773227758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/3\/413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":238,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["biom16030413"],"URL":"https:\/\/doi.org\/10.3390\/biom16030413","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]}}}